Ventripoint Announces Appointment of Chief Finance Officer
Toronto, Ontario - TheNewswire - June 3, 2020 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"), (TSXV:VPT) wishes to announce that Victor Hugo has been appointed the CFO of Ventripoint pursuant to a consulting agreement with Marrelli Support Services Inc.
As previously announced, Ellen Briant resigned as CFO of the Corporation in December, 2019. Mr. George Adams has been Acting CFO. The Board of Directors would like to thank Ellen Briant for her many years of excellent service and for assisting in the transition of all accounting and CFO functions to Mr. Hugo, as well as completing the annual financial audit, which was recently filed for the year ending December 31, 2019.
Mr. Hugo is a senior financial analyst at Marrelli Support Services Inc., providing CFO, accounting, regulatory compliance, and management advisory services to numerous issuers on the TSX, TSX-Venture and other Canadian and US exchanges. His public company experience includes preparation of financial statements, initial public offerings and business combinations transactions. He serves as Chief Financial Officer to a number of junior companies listed on the TSX Venture and Canadian Securities Exchanges. Previously, he was the head of the Finance departments at Barrick Gold's Hemlo operation (2016 - 2017) and Nystar's Myra Falls mine (2013 - 2016). Mr. Hugo is a CPA, CMA and holds a Bachelors of Commerce with Honours specializing in Accounting and Cost and Management Accounting from Potchefstroom University in South Africa.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, please contact:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.